Vaccinex Reports Clinical Benefit In Interim Analyses From Two Phase 2 Studies Of Pepinemab Combination Treatment At Society For Immunotherapy Of Cancer's Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Vaccinex, Inc. (NASDAQ:VCNX) will present findings from two Phase 2 studies of its lead product, pepinemab, at the Society for Immunotherapy of Cancer's Annual Meeting. The studies show pepinemab's ability to induce the formation of lymphoid structures in tumors, improving outcomes to immune checkpoint inhibitors. In one study, pepinemab combined with Merck's KEYTRUDA doubled objective responses and progression free survival in patients with hard-to-treat tumors. Another study with Emory University showed pepinemab, combined with nivolumab and/or ipilimumab, prevented tumor recurrence for over 2 years in patients.
October 31, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaccinex's pepinemab shows promising results in Phase 2 studies, potentially improving the company's market position in cancer treatment.
The positive results from the Phase 2 studies of Vaccinex's lead product, pepinemab, could potentially improve the company's market position in cancer treatment. The studies show that pepinemab, when combined with other therapies, can improve outcomes in patients with hard-to-treat tumors. This could lead to increased demand for the product, potentially boosting Vaccinex's revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100